Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6255661 | 0.90 | HRH3 (0.49) | ALDH1A1KDM4EHRH3SMN1; SMN2MAPT | |
| SCHEMBL17069861 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EDRD4DRD2DRD3 | |
| SCHEMBL15782889 | 0.82 | L3MBTL1 (0.52) | DRD4DRD2DRD3HRH3PPARA | |
| SCHEMBL9935752 | 0.82 | LTA4H (0.53) | DRD4DRD2DRD3HRH3LMNA | |
| SCHEMBL28308603 | 0.81 | HRH3 (0.41) | ALDH1A1KDM4EHRH3SMN1; SMN2MAPT | |
| SCHEMBL16647614 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EDRD4DRD2DRD3 | |
| SCHEMBL9935748 | 0.81 | HRH3 (0.43) | HRH3SMN1; SMN2MAPTPPARAL3MBTL1 | |
| SCHEMBL9592060 | 0.81 | SMN1; SMN2 (0.53) | KDM4EHRH3SMN1; SMN2LMNAMAOB | |
| SCHEMBL18034737 | 0.81 | TDP1 (0.52) | ALDH1A1HRH3SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL941289 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EDRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-20240199621-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-112585147-B | MAP4K4 inhibitors | 帝国理工学院创新有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| WO-2023134753-A1 | TUBULIN-SRC DUAL TARGET INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444425-A | tubulin-SRC dual target inhibitors | 武汉人福创新药物研发中心有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230055250-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| EP-3055288-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051496-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | ALDH1A1 3088/4885KDM4E 4142/4885DRD4 1847/4885 |
| US-20230055250-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K5, MAP4K1 | ALDH1A1 2176/4885KDM4E 1003/4885DRD4 4537/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | ALDH1A1 2176/4885KDM4E 1003/4885DRD4 4537/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | ALDH1A1 1426/4885KDM4E 742/4885DRD4 3777/4885 |
| US-20240199621-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | ALDH1A1 1426/4885KDM4E 742/4885DRD4 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.